Killing effect of interleukin-13 receptor alpha 2 (IL-13Rα2) sensitized DC-CTL cells on human glioblastoma U251 cells

Cellular Immunology

Volumn 263, Issue 2, 2010, Pages 172-175

  Yan, Xinjiang ^a   Su, Zhipeng ^a   Zhang, Jing ^b   Wu, Zhebao ^a   Ye, Sheng ^a   Lu, Xianghe ^a   Wu, Jinsen ^a   Zeng, Yanjun ^c   Zheng, Weiming ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c BEIJING UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

CD8 positive T lymphocyte (CTL); Dendritic cell; Glioblastoma multiforme; IL 13R 2 antigen peptide; Immunotherapy; Plasmid

Indexed keywords

INTERLEUKIN 13 RECEPTOR ALPHA2;

ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL COUNT; CELL STRAIN U251; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; OPTICAL DENSITY; PRIORITY JOURNAL;

BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; GLIOBLASTOMA; HUMANS; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 77953361279     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2010.03.013     Document Type: Article

References (24)

1. Deorah S., Lynch C.F., Sibenaller Z.A. Trends in brain cancer incidence, survival in the United States: surveillance, epidemiology, results program, 1973-2001. Neurosurg. Focus. 2006, 20(4):E1.
2. Davis I.D., Jefford M., Parente P., Cebon J. Rational approaches to human cancer immunotherapy. J. Leukoc. Biol. 2003, 73:3-29.
3. Sehnurr M., Galambos P., Scholz C. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res. 2001, 61:6445-6450.
4. Ashley D.M., Faiola B., Nair S. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induced antitumor immunity against central nervous system tumors. J. Exp. Med. 1997, 186:1177-1182.
5. Yu J.S., Wheeler C.J., Zeltzer P.M. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 2001, 61:842-847.
6. Kalady M.F., Onaitis M.W., Padilla K.N. Enhanced dendritic cell antigen presentation in RNA-based immunotherapy. J. Surg. Res. 2002, 105:17-24.
7. Schnurr M., Scholz C., Rothenfusser S. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and γ δ T cells. Cancer Res. 2002, 62:2347-2352.
8. Jefford M., Maraskovsky E., Cebon J. The use of dendritic cells in cancer therapy. Lancet Oncol. 2001, 2:343-353.
9. Rosenberg S.A., White D.E. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol. 1996, 19:81-84.
10. Tatsis E., Reinhold-Keller E., Steindorf K. Wegener's granulomatosis associated with renal cell carcinoma. Arthritis Rheum. 1999, 42:751-756.
11. Ludewig B., Ochsenbein A.F., Odermatt B. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J. Exp. Med. 2000, 191:795-804.
12. Yu Wenqiao., Su Zhipeng., Wu Zhebao. CDNA clone, prokaryotic expression and purification of human interleukin-13 receptor {alpha}2 chain. Cancer Immunol. Immunother. 2008, 58:409-413.
13. Bakker A.B., Marland G., de Boer A.J. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res. 1995, 55:5330-5334.
14. Miyoshi N., Oubrahim H., Choch P.B. Age-dependent cell death and the role of ATP in hydrogen peroxide-induced apoptosis and necrosis. J. Pro. Natl. Acad. Sci. USA 2006, 103(6):1727-1731.
15. Dhodapkar M.V., Krasovsky J., Steinman R.M. Mature dendritic cells boost functionally superior CD8 (±) T-cell in humans without foreign helper epitopes. J. Clin. Invest. 2000, 105:R9-R14.
16. Schuler G., Schuler-Thurner B., Steinman R.M. The use of dendritic cells in cancer immunotherapy. J. Curr. Opin. lmmunol. 2003, 15:138-147.
17. Märten A., Schöttker B., Ziske C. Increase of the immunostimulatory effect of dendritic cells by pulsing with CA19-9 protein. J. Immunother. 2000, 23:464-472.
18. Liau L.M., Prins R.M., Kiertscher S.M. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res. 2005, 11:5515-5525.
19. Yu John S., Liu Gentao, Ying Han. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-Cells in patients with malignant glioma. Cancer Res. 2004, 64:4973-4979.
20. Kawakami M., Kawakami K., Takahashi S. Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors. Cancer 2004, 101:1036-1042.
21. Kawakami K., Kioi M., Liu Q., Kawakami M. Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy. J. Immunother. 2005, 28:193-202.
22. Joshi B.H., Plautz G.E., Puri R.K. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignantgliomas. Cancer Res. 2000, 60:1168-1172.
23. Takahashi H., Nakada T., Puisieux I. Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science 1993, 259:1460-1463.
24. Schmidt-Wolf I.G., Lefterova P., Mehta B.A. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp. Hematol. 1993, 21:1673-1679.